Background: Chemotherapy induced nausea- vomiting (CINV) is considered as the most common, feared and most troublesome side effect of chemotherapy. NEPA (NEtupitant 300 mg + PAlonosetron 0.50 mg) is the first commercially available oral fixed-dose combination (FDC) of two active antiemetic agents in India. The present study was planned to evaluate the effectiveness of NEPA in the real world setting of India.

Methods: This was a multicentric retrospective study conducted in two centers in India. The data of all chemonaive patients, who were prescribed NEPA was analyzed. Effectiveness i.e. complete response and complete protection in controlling overall, acute and delayed phase was analyzed.

Results: A total of 329 patients were enrolled in the study. 260 received highly emetogenic chemotherapy (HEC) regimen and 69 received moderately emetogenic chemotherapy (MEC) regimen. Among all the enrolled patients, complete response in acute, delayed and overall phase was 93, 85.71 and 85.41% respectively; and completed protection was 88.44, 81.76 and 80.54% respectively. Those who received HEC regimen, the completed response and complete protection in overall phase was 84.61 and 79.61% respectively and those who received MEC regimen the completed response and complete control in overall phase was 84.05 and 84.05% respectively.

Conclusion: A single oral dose of NEPA targeting dual pathways showed effective control of nausea-vomiting in patients on the HEC and MEC regimens and had good control over nausea-vomiting in acute, delayed and overall phase of nausea-vomiting.

Similar articles

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.
Gralla RJ, Bosnjak SM, Hontsa A, Balser C, Rizzi G, Rossi G, Borroni ME, Jordan K. Gralla RJ, et al. Ann Oncol. 2014 Jul;25(7):1333-1339. doi: 10.1093/annonc/mdu096. Epub 2014 Mar 14. Ann Oncol. 2014. PMID: 24631949 Free PMC article. Clinical Trial.
A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.
Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwartzberg L, Grunberg S. Aapro M, et al. Ann Oncol. 2014 Jul;25(7):1328-1333. doi: 10.1093/annonc/mdu101. Epub 2014 Mar 5. Ann Oncol. 2014. PMID: 24603643 Free PMC article. Clinical Trial.
Single-dose netupitant/palonosetron?versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a?pooled analysis.
Navari RM, Binder G, Bonizzoni E, Clark-Snow R, Olivari S, Roeland EJ. Navari RM, et al. Future Oncol. 2021 Aug;17(23):3027-3035. doi: 10.2217/fon-2021-0023. Epub 2021 Apr 21. Future Oncol. 2021. PMID: 33878896
A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
Zhang L, Lu S, Feng J, Dechaphunkul A, Chang J, Wang D, Chessari S, Lanzarotti C, Jordan K, Aapro M. Zhang L, et al. Ann Oncol. 2018 Feb 1;29(2):452-458. doi: 10.1093/annonc/mdx698. Ann Oncol. 2018. PMID: 29092012 Free PMC article. Clinical Trial.
Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting.
Keating GM. Keating GM. Drugs. 2015 Dec;75(18):2131-41. doi: 10.1007/s40265-015-0512-9. Drugs. 2015. PMID: 26613606 Review.

The effectiveness of NEPA in the prevention of chemotherapy-induced nausea vomiting among chemo naive patients in an Indian setting

Abstract

Conflict of interest statement

Similar articles